Addition and omission analogs of the 13-residue antibacterial and hemolytic peptide PKLLKTFLSKWIG: structural preferences, model membrane binding and biological activities.
The consequences of selective addition or deletion of polar amino acids in a 13-residue antibacterial peptide PKLLKTFLSKWIG on structure, membrane binding and biological activities have been investigated. The variants generated are (a) S and T residues replaced by K, (b) S and T residues deleted individually and together, (c) introduction of two additional K and (d) deletion of L and L with T. In the aqueous environment all the peptides were unordered. In trifluoroethanol, the spectra of peptides belonging to groups (a-c) suggest distorted helical conformation. Peptides in group (d) appear to adopt beta-sheet conformation. The peptides bind to zwitterionic and negatively charged lipid vesicles, although to different extents. With the exception of peptides in group (d), all the other peptides exhibited comparable antibacterial activity against Escherichia coli and Staphylococcus aureus. However, the changes made in the peptides in groups (a-c) resulted in reduction of hemolytic activity compared to the parent peptide. Extent of binding to lipid vesicles composed of phosphatidylcholine and cholesterol appears to correlate with hemolytic activity. It appears that polar and charged residues play a major role in modulating the biological activities of the 13-residue peptide PKLLKTFLSKWIG. The 11-residue peptide-like PKLLKFLKWIG has selective antibacterial activity. Thus, by judicious engineering it should be possible to generate short peptides with selective antibacterial activity.
Bikshapathy
E
E
Centre for Cellular and Molecular Biology, Hyderabad, India.
Sitaram
N
N
Nagaraj
R
R
D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000378:metabolism; D002942:Circular Dichroism; D004912:Erythrocytes / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D005453:Fluorescence; D006461:Hemolysis / Q000187:drug effects*; D008081:Liposomes / Q000378:metabolism; D009842:Oligopeptides / Q000737:chemistry* / Q000494:pharmacology; D010455:Peptides; D017433:Protein Structure, Secondary; D011506:Proteins / Q000737:chemistry* / Q000494:pharmacology; D051381:Rats; D013211:Staphylococcus aureus / Q000187:drug effects; D014270:Trifluoroethanol / Q000494:pharmacology; D014364:Tryptophan / Q000737:chemistry
D000900:Anti-Bacterial Agents; D008081:Liposomes; D009842:Oligopeptides; D010455:Peptides; D011506:Proteins; C119236:prolyl-lysyl-leucyl-leucyl-lysyl-threonyl-phenylalanyl-leucyl-seryl-lysyl-tryptophyl-isoleucyl-glycine; D014270:Trifluoroethanol; D014364:Tryptophan